CHMP recommends adoption of Novartis Cushing's orphan
This article was originally published in Scrip
Executive Summary
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) have recommended approval of Signifor (pasireotide), a somatostatin analogue developed by Novartis, as a treatment of Cushing's disease in patients who cannot have surgery or for whom surgery failed. The European Commission would be expected to either accept or reject the recommendation within three months.